Answers are grounded in this paper and cite their sources.
Background This study aimed to evaluate the association between the Hepatic Steatosis Index (HSI) and the Fatty Liver Index (FLI), both serving as surrogate indices of hepatic steatosis, and breast cancer risk among Korean women. Methods This nationwide cohort study included 3,629,375 women aged ≥40 years who participated in a national breast cancer screening program between 2009 and 2010. HSI and FLI were categorized as follows: HSI (<30, 30-35.9, ≥36) and FLI (<30, 30-59.9, ≥60). Combined HSI and FLI categories were also examined. Cox proportional hazards regression and restricted cubic spline models were used to estimate the associations. Results Postmenopausal women with HSI ≥36 and FLI ≥60 had significantly higher risks of breast cancer (hazard ratios [HRs] 1.48, 95% confidence intervals [CIs] 1.43-1.53; HR 1.41, 95% CI 1.35-1.47, respectively) than those in the lowest groups, whereas no significant associations were observed among women who were premenopausal at baseline. Combined HSI-FLI analyses showed the highest breast cancer risk among women classified as high-risk by both indices (HR 1.68, 95% CI 1.59-1.77). Conclusions Higher HSI and FLI were associated with an increased risk of breast cancer in postmenopausal women, demonstrating a dose-response relationship. These findings highlight the potential role of metabolic liver dysfunction in the development of postmenopausal breast cancer. Impact These findings support the role of metabolic liver dysfunction in postmenopausal breast carcinogenesis and suggest that simple, noninvasive fatty liver indices may help identify women who could benefit from targeted prevention strategies.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: